The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)

Aims Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of zolmitriptan (311C90), a novel 5HT(1D) agonist for the acute treatment of migraine. Methods After an initial test i.v. infusion, bioavailabilty was assessed by comparison...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Seaber, E., On, N., Dixon*, R. M., Gibbens, M., Leavens, W. J., Liptrot, J., Chittick, G., Posner, J., Rolan†, P. E., Peck, R. W.
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley-Blackwell 1997
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2042784/
https://ncbi.nlm.nih.gov/pubmed/9205817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1997.00614.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados